Abzena Announces Expansion of Integrated Biologics Offering with the Addition of Preformulation and Formulation Capability
Dr. Jonathan Goldman, CEO, Abzena, announced that Abzena has augmented existing discovery to GMP drug substance and Antibody Drug Conjugates (ADC) manufacturing and associated analytical services with numerous investments in preformulation and formulation capabilities to enable de-risking of CTA/IND candidates. Abzena’s existing expertise in analytical assessment of biologics and ADCs is strengthened with the addition of […] Read more
Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment
Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity and extra chemistry laboratory space. Appointment of Richard Milbank as Chief Financial Officer. San Diego, CA, Bristol, PA and Cambridge, UK 6th Nov. 2018 – Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 […] Read more
Ken Cunningham, Chairman of Abzena Limited, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO) following completion of the Acquisition by Welsh, Carson, Anderson & Stowe (WCAS)
Dr. Goldman will focus his efforts on the growth of Abzena as the leading provider of outsourced and integrated services in the biologics early development space by establishing new partnerships with clients, building internal manufacturing capacity and pursuing strategic acquisitions. He joins the company after achieving significant success as the CEO of Aptuit LLC, a […] Read more
Abzena announces a research and licence agreement with Tmunity Therapeutics, a T cell engineering company
Cambridge, UK, 19 September 2018 – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen […] Read more
Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)
Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody™ platform. Faron will develop Clevegen®, a novel anti-Clever-1 antibody, for the treatment of selected metastatic or inoperable tumours. It’s great to see an ABZENA Inside product […] Read more
Release of first GMP drug substance for an ABZENA Inside product manufactured by Abzena
Cambridge, UK, 8 August 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody platform™. The product is a novel therapeutic […] Read more
Abzena signs protein engineering agreement with NYU Langone Health
Cambridge, UK, 30 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug […] Read more
Abzena and Telix sign strategic manufacturing and bioconjugation agreement
Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals Limited (‘Telix’). The agreements have a combined value of $5.9 million and these projects are […] Read more
Notice of full year results
Cambridge, UK, 29 May 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full-year results for the year to 31 March 2018 on Monday, 4 June 2018. A presentation for analysts will be held at 09:30 […] Read more
Abzena hosts first Biopharmaceutical Discovery and Development Symposium and open day at Cambridge, UK site
Cambridge, UK, 26 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, is today hosting its first Biopharmaceutical Discovery and Development Symposium and open day, showcasing its new facility at the Babraham Research Campus in Cambridge, UK. The Symposium […] Read more